Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Tax Provisions (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Tax Provisions for 10 consecutive years, with $82.7 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 24.36% to $82.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.9 million through Dec 2025, up 16.22% year-over-year, with the annual reading at $129.9 million for FY2025, 16.22% up from the prior year.
  • Tax Provisions for Q4 2025 was $82.7 million at BeOne Medicines, up from $22.3 million in the prior quarter.
  • The five-year high for Tax Provisions was $82.7 million in Q4 2025, with the low at -$15.4 million in Q4 2021.
  • Average Tax Provisions over 5 years is $16.3 million, with a median of $13.8 million recorded in 2023.
  • The sharpest move saw Tax Provisions crashed 397.94% in 2021, then surged 3639.57% in 2022.
  • Over 5 years, Tax Provisions stood at -$15.4 million in 2021, then surged by 193.59% to $14.4 million in 2022, then rose by 16.78% to $16.8 million in 2023, then soared by 296.46% to $66.5 million in 2024, then rose by 24.36% to $82.7 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $82.7 million, $22.3 million, and $5.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.